Fluticasone propionate - Glaxo Wellcome

Drug Profile

Fluticasone propionate - Glaxo Wellcome

Alternative Names: Flixotide; Flixotide Evohaler; Flixotide Nebules

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Glaxo Wellcome SA
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 28 Sep 2016 Discontinued - Phase-II for Asthma in New Zealand (Inhalation)
  • 03 Aug 2016 Glaxo Wellcome initiates a phase III trial in Asthma (Prevention) in China (Inhalation) (EudraCT2015-004870-14)
  • 19 May 2016 Launched for Asthma (Prevention) in Israel (Inhalation) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top